- Previous Close
0.3700 - Open
0.3550 - Bid 0.3550 x --
- Ask 0.3800 x --
- Day's Range
0.3500 - 0.3800 - 52 Week Range
0.1600 - 0.6200 - Volume
82,354 - Avg. Volume
159,388 - Market Cap (intraday)
48.83M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company provides CleoDX pre-surgical triage tests which measures a combination of biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property and patents. The company was incorporated in 2021 and is based in Melbourne, Australia.
www.cleodx.comRecent News: COV.AX
View MorePerformance Overview: COV.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COV.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COV.AX
View MoreValuation Measures
Market Cap
48.83M
Enterprise Value
50.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.46%
Return on Equity (ttm)
-34.46%
Revenue (ttm)
210.81k
Net Income Avi to Common (ttm)
-3.1M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
7.31M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-197.57k